# Pioglitazone and Insulin Resistance in ADT

> **NCT05098327** · PHASE3 · WITHDRAWN · sponsor: **State University of New York at Buffalo**

## Conditions studied

- Prostate Cancer
- Insulin Resistance
- Diabetes Mellitus, Type 2
- Androgen Deficiency

## Interventions

- **DRUG:** Pioglitazone 30 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05098327
- **Lead sponsor:** State University of New York at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no participant enrolled due to lack of interest.
- **Last updated:** 2023-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098327, "Pioglitazone and Insulin Resistance in ADT". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05098327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*